Form 8-K - Current report
September 10 2024 - 4:05PM
Edgar (US Regulatory)
false
0001280776
0001280776
2024-09-10
2024-09-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 10, 2024
IMMUNIC, INC.
(Exact name of registrant as specified in its
charter)
Delaware |
001-36201 |
56-2358443 |
(State or other jurisdiction
of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
1200 Avenue of the Americas, Suite 200
New York, NY 10036
USA
(Address of principal executive offices)
Registrant’s telephone number, including
area code: (332) 255-9818
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of exchange on which registered |
Common Stock, par value $0.0001 |
IMUX |
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. Yes ☐ No ☐
Item 8.01. Other Events.
On September 10, 2024, Immunic,
Inc. (the “Company”) hosted its multiple sclerosis research and development day (“R&D Day”),
a scientific conference dedicated to certain multiple sclerosis-related therapeutic matters and aspects of vidofludimus calcium (IMU-838)
in connection with the product candidate’s future possible ability to treat relapsing and progressive multiple sclerosis patients,
respectively.
In the course of R&D Day,
the Company presented certain information to attendees of R&D Day (the “Presentation”). A copy of the Presentation
is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in Item 8.01
of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for the purposes of Section
18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange
Act, except as shall be expressly set forth therein.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this Current Report on Form 8-K and the Presentation
are “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided
by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this Current
Report on Form 8-K and the Presentation regarding strategy, future operations, future financial position, future revenue, projected expenses,
sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management
are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic’s development
programs and the targeted diseases; the potential for Immunic’s development programs to safely and effectively target diseases;
preclinical and clinical data for Immunic’s development programs; the timing of current and future clinical trials and anticipated
clinical milestones; the nature, strategy and focus of the Company and further updates with respect thereto; the development and commercial
potential of any product candidates of the Company; and the Company's expected cash runway. Immunic may not actually achieve the plans,
carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place
undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial
risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation, the COVID-19 pandemic, increasing inflation, impacts of the Ukraine –
Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the
ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability
of sufficient financial and other resources to meet business objectives and operational requirements, including the ability to satisfy
the minimum average price and trading volume conditions required to receive funding in tranche 2 and 3 of the January 2024 private placement,
the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, the
protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory
approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties
and other factors can be found in the section captioned "Risk Factors," in the Company's Annual Report on Form 10-K for the
fiscal year ended December 31, 2023, filed with the SEC on February 22, 2024, and in the Company's subsequent filings with the SEC. Copies
of these filings are available online at www.sec.gov or ir.imux.com/sec-filings.
The statements made in this Current Report on Form 8-K and the Presentation
speak only as of the date stated herein, and subsequent events and developments may cause the Company’s expectations and beliefs
to change. While the Company may elect to update these forward-looking statements publicly at some point in the future, the Company specifically
disclaims any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law. These
forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date stated herein.
Item 9.01. Financial Statements and Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
Dated: September 10, 2024 |
Immunic, Inc. |
|
|
|
|
By: |
/s/ Daniel Vitt |
|
|
Daniel Vitt |
|
|
Chief Executive Officer |
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide1.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide2.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide3.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide4.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide5.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide6.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide7.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide8.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide9.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide10.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide11.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide12.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide13.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide14.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide15.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide16.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide17.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide18.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide19.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide20.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide21.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide22.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide23.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide24.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide25.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide26.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide27.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide28.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide29.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide30.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide31.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide32.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide33.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide34.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide35.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide36.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide37.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide38.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide39.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide40.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide41.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide42.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide43.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide44.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide45.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide46.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide47.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide48.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide49.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide50.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide51.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide52.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide53.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide54.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide55.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide56.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide57.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide58.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide59.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide60.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide61.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide62.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide63.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide64.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide65.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide66.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide67.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide68.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide69.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide70.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide71.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide72.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide73.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide74.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide75.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide76.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide77.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide78.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide79.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide80.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide81.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide82.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide83.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide84.jpg)
![](https://www.sec.gov/Archives/edgar/data/1280776/000119380524001102/slide85.jpg)
v3.24.2.u1
Cover
|
Sep. 10, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Sep. 10, 2024
|
Entity File Number |
001-36201
|
Entity Registrant Name |
IMMUNIC, INC.
|
Entity Central Index Key |
0001280776
|
Entity Tax Identification Number |
56-2358443
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
1200 Avenue of the Americas
|
Entity Address, Address Line Two |
Suite 200
|
Entity Address, City or Town |
New York
|
Entity Address, State or Province |
NY
|
Entity Address, Country |
US
|
Entity Address, Postal Zip Code |
10036
|
City Area Code |
(332)
|
Local Phone Number |
255-9818
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, par value $0.0001
|
Trading Symbol |
IMUX
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionISO 3166-1 alpha-2 country code.
+ References
+ Details
Name: |
dei_EntityAddressCountry |
Namespace Prefix: |
dei_ |
Data Type: |
dei:countryCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Immunic (NASDAQ:IMUX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Immunic (NASDAQ:IMUX)
Historical Stock Chart
From Sep 2023 to Sep 2024